Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Recurrent Prostate Cancer

Interventions: Other: laboratory biomarker analysis
Procedure: quality-of-life assessment
Other: questionnaire administration
Drug: cinacalcet hydrochloride

Registration Number: NCT01054079

Lead Sponsor: Wake Forest University Health Sciences

Brief Summary: This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment

Detailed Description: PRIMARY OBJECTIVES:

I. To test the hypothesis that once-daily treatment with 30 mg of cinacalcet hydrochloride (Sensipar) will reduce the rate of rise of serum prostate-specific antigen (PSA) compared to pre-treatment PSA values in subjects with biochemically recurrent prostate cancer after failed definitive local therapy.

OUTLINE:

Patients receive cinacalcet hydrochloride orally (PO) once daily (QD) for 20 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.

Recruitment & Eligibility

Status: COMPLETED

Sex: Male

Target Recruitment: 20

Inclusion Criteria

Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
For patients who have recurrent disease following surgery as first line therapy ("surgical failures")
PSA requirement is 0.2 ng/ml or above
For patients who have recurrent disease following radiation as first line therapy, the eligibility follows the "Phoenix criteria", that is, a rise of 2 ng/mL over the PSA nadir
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Granulocytes >= 1000/uL
Serum creatinine =< 2.0 mg/dl
Total serum calcium > 9.0 and < 10.5 mg/dl
Total bilirubin =< 2.0 mg/dl
Platelet count >=100,000/uL
Hemoglobin (Hgb) >= 9 g/dL
Total testosterone >= 50 ng/dL
Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative)

Exclusion Criteria

Serious medical illness which would limit survival to less than 3 months
Active, uncontrolled bacterial, viral or fungal infection
Hemorrhagic disorder
Any radiographic evidence of metastatic disease including positive bone scan or computed tomography (CT) abdomen/pelvis
History of hypocalcemia or seizure disorder
Patients with known hypersensitivity to any of the components of cinacalcet (cinacalcet hydrochloride)

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (cinacalcet hydrochloride)	questionnaire administration	Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (cinacalcet hydrochloride)	laboratory biomarker analysis	Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (cinacalcet hydrochloride)	quality-of-life assessment	Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (cinacalcet hydrochloride)	cinacalcet hydrochloride	Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Rate of Rise of Serum PSA	24 weeks	The difference of post treatment and pre-enrollment PSA.For those with multiple PSA measures post we use the median of those measures to estimate the participant's post PSA level.

Secondary Outcome Measures

Name	Time	Method
Change in Quality of Life (QOL) as Assessed by the Brief Male Sexual Inventory	Up to 20 weeks	The Brief Male Sexual Inventory is an 11 question assessment including subscales: sex drive, erections, ejaculation. The scores are totaled to produce an overall score with a range of 1-45, with higher score indicating worse outcomes.
Change in Functional Assessment of Cancer Therapy-Prostate (FACT-P)	up to 20 weeks	The FACT-P is a multidimensional, self-report QoL instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores for each domain, as well as a global QoL score. All subscale items are summed to a total. The score range is 0-156. Higher scores represent better quality of life.
Change in Hormonal Assessment Scale From Expanded Prostate Cancer Index Composite (EPIC)	up to 20 weeks	The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Epic produces two scores, one for function (5 items) and the other for bother (6 items). The response for each item is standardized to a 0 to 100 scale. For both scales, higher scores indicate worse outcomes.
Change in Total and Free Testosterone	Up to 20 weeks	The detectable difference is estimated using a paired t-test approach. The lab measure will also be analyzed longitudinally using all measures with a mixed model approach adjusting for individual covariates.